---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-001826"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T02:35:39.308639+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aclaris Q4 net loss $27.6M; revenue $7.8M on licensing; cash $229.8M through 2025

## Summary
- Q4 2022 net loss $27.6M vs $22.8M in Q4 2021; full-year net loss $86.9M vs $90.9M.
- Q4 total revenue $7.8M (incl. $6.7M licensing, $5M from Pediatrix) vs $1.5M prior year.
- Cash, equivalents and marketable securities $229.8M; expected to fund operations through end of 2025.
- Phase 2a zunsemetinib HS topline data expected March 2023; Phase 2b RA data H2 2023.
- Phase 2b ATI-1777 atopic dermatitis topline data mid-2023; Phase 1 MAD ATI-2138 data H2 2023.

## SEC filing metadata
- accession: 0001558370-23-001826
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000155837023001826/0001558370-23-001826-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000155837023001826/acrs-20230223x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-001826
- JSON: https://secwatch.observer/filing/0001558370-23-001826.json
- Plain text: https://secwatch.observer/filing/0001558370-23-001826.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.